Health Care • Medical/Dental Instruments
$11.37 ▼ -0.08
(-0.70%)
MKT CAP: $1.76B • VOL: 7.22M
52W L $7 52W H $23
ROARABLE / RQD
D- • 38/100
PIOTROSKI
6 / 9
ATEC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $764.2M | $611.6M | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $531.9M | $424.3M | — |
| Gross Margin % | 69.6% | 69.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$82.1M | -$136.2M | -$173.4M |
| Operating Margin % | -10.7% | -22.3% | — |
| Net Income (GAAP) | -$143.4M | -$162.1M | -$186.6M |
| EBITDA (Normalized) | -$48.2M | -$69.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $45.2M | -$44.7M | -$78.5M |
| Capital Expenditures (CapEx) | $42.5M | $83.2M | — |
| Free Cash Flow (FCF) | $2.8M | -$127.9M | -$78.5M |
| FCF Margin % | 0.4% | -20.9% | — |
| Return on Invested Capital (ROIC %) | -18.4% | -25.5% | — |
| Cash & Short-Term Equivalents | $160.8M | $138.8M | — |
| Total Debt (Short + Long Term) | $501.4M | $574.5M | — |
| Total Stockholders' Equity | $12.4M | -$14.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ATEC.